Fabry nephropathy: 5 years of enzyme replacement therapy-a short review.
作者信息
Barbey Frédéric, Lidove Olivier, Schwarting Andreas
机构信息
Service of Transplantation and Department of Nephrology, Centre Hospitalier Universitaire Vaudois and Lausanne University, Switzerland.
Department of Internal Medicine, Faculté de Médecine Xavier Bichat, Bichat Hospital, Université Paris 7, Paris, France.
出版信息
NDT Plus. 2008 Feb;1(1):11-19. doi: 10.1093/ndtplus/sfm022. Epub 2007 Dec 19.
Abstract
摘要
相似文献
1
Fabry nephropathy: 5 years of enzyme replacement therapy-a short review.法布里肾病：酶替代疗法5年——简短综述
NDT Plus. 2008 Feb;1(1):11-19. doi: 10.1093/ndtplus/sfm022. Epub 2007 Dec 19.
2
Enzyme replacement therapy and Fabry nephropathy.酶替代疗法与法布里肾病。
Clin J Am Soc Nephrol. 2010 Feb;5(2):371-8. doi: 10.2215/CJN.06900909. Epub 2009 Dec 10.
3
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.抗蛋白尿治疗与法布里肾病：接受β-半乳糖苷酶替代酶替代疗法患者蛋白尿的持续减少
J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26.
4
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.一项关于血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂对糖尿病肾病影响的回顾性研究。
Indian J Pharmacol. 2015 Mar-Apr;47(2):148-52. doi: 10.4103/0253-7613.153420.
5
[Diabetic nephropathy and ACE inhibitors].[糖尿病肾病与血管紧张素转换酶抑制剂]
Clin Res Cardiol. 2006 Jan;95 Suppl 1:i83-7. doi: 10.1007/s00392-006-1103-2.
6
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for IgA nephropathy.用于IgA肾病的血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂。
Semin Nephrol. 2004 May;24(3):218-24. doi: 10.1016/j.semnephrol.2004.01.003.
7
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison.血管紧张素转换酶抑制剂与血管紧张素受体阻滞剂治疗糖尿病肾病的回顾性比较。
J Renin Angiotensin Aldosterone Syst. 2009 Dec;10(4):195-200. doi: 10.1177/1470320309352352.
8
9
Antiproteinuric therapy and Fabry nephropathy: factors associated with preserved kidney function during agalsidase-beta therapy.抗蛋白尿治疗与法布里肾病：在阿加糖酶β治疗期间与肾功能保留相关的因素
J Med Genet. 2015 Dec;52(12):860-6. doi: 10.1136/jmedgenet-2015-103471. Epub 2015 Oct 21.
10
Agalsidase alfa slows the decline in renal function in patients with Fabry disease.阿加糖酶α可减缓法布里病患者肾功能的下降。
Am J Nephrol. 2009;29(5):353-61. doi: 10.1159/000168482. Epub 2008 Oct 31.
引用本文的文献
1
Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat.溶酶体α-半乳糖苷酶 a 在果蝇模型中的错误折叠及其被药物伴侣米加司他缓解。
Int J Mol Sci. 2020 Oct 7;21(19):7397. doi: 10.3390/ijms21197397.
2
Immune-Mediated Myocarditis in Fabry Disease Cardiomyopathy.法布里病心肌病中的免疫介导性心肌炎。
J Am Heart Assoc. 2018 Sep 4;7(17):e009052. doi: 10.1161/JAHA.118.009052.
3
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.从阿加糖酶α转换为阿加糖酶β作为法布里病的酶替代疗法后血浆葡萄糖神经酰胺水平的降低。
JIMD Rep. 2016;25:95-106. doi: 10.1007/8904_2015_483. Epub 2015 Aug 25.
4
Innate and Adaptive Immune Response in Fabry Disease.法布里病中的先天性和适应性免疫反应。
JIMD Rep. 2015;22:1-10. doi: 10.1007/8904_2014_371. Epub 2015 Feb 18.
5
Sometimes when you hear hoof beats, it could be a zebra: consider the diagnosis of Fabry disease.有时候，当你听到马蹄声时，它可能是斑马：考虑诊断法布里病。
BMC Nephrol. 2012 Jul 31;13:73. doi: 10.1186/1471-2369-13-73.
6
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.阿加糖酶α长期治疗法治疗法布雷肾病的疗效。
Clin J Am Soc Nephrol. 2012 Jan;7(1):60-9. doi: 10.2215/CJN.03130411.
7
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).法布瑞氏病肾脏病理记分系统：国际法布瑞氏肾病研究组（ISGFN）报告。
Nephrol Dial Transplant. 2010 Jul;25(7):2168-77. doi: 10.1093/ndt/gfp528. Epub 2009 Oct 15.
8
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.酶替代疗法治疗法布里病肾病的安全性和有效性。
Biologics. 2008 Dec;2(4):823-43. doi: 10.2147/btt.s3770.
9
Agalsidase alfa and kidney dysfunction in Fabry disease.阿加糖酶α与法布里病中的肾功能障碍
J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8.
10
Disease recurrence in paediatric renal transplantation.小儿肾移植中的疾病复发
Pediatr Nephrol. 2009 Nov;24(11):2097-108. doi: 10.1007/s00467-009-1137-6. Epub 2009 Feb 27.
本文引用的文献
1
Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.抗体形成对阿加糖酶β治疗期间法布里病患者尿液中球三糖神经酰胺（GL-3）减少的影响。
Mol Genet Metab. 2007 Nov;92(3):271-3. doi: 10.1016/j.ymgme.2007.06.013. Epub 2007 Aug 8.
2
Cellular and tissue localization of globotriaosylceramide in Fabry disease.法布里病中球三糖神经酰胺的细胞和组织定位
Virchows Arch. 2007 Oct;451(4):823-34. doi: 10.1007/s00428-007-0468-6. Epub 2007 Aug 3.
3
Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.抗蛋白尿治疗与法布里肾病：接受β-半乳糖苷酶替代酶替代疗法患者蛋白尿的持续减少
J Am Soc Nephrol. 2007 Sep;18(9):2609-17. doi: 10.1681/ASN.2006121400. Epub 2007 Jul 26.
4
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.法布里病的治疗：阿加糖酶α或β 0.2mg/kg 剂量比较试验的结果。
PLoS One. 2007 Jul 11;2(7):e598. doi: 10.1371/journal.pone.0000598.
5
Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.法布里病患者接受54个月的阿加糖酶β治疗后实现持续、长期的肾脏功能稳定。
J Am Soc Nephrol. 2007 May;18(5):1547-57. doi: 10.1681/ASN.2006080816. Epub 2007 Apr 4.
6
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.对于长期每两周给药一次的法布里病患者，每周进行酶替代疗法可能会减缓肾功能下降。
J Am Soc Nephrol. 2007 May;18(5):1576-83. doi: 10.1681/ASN.2006111263. Epub 2007 Apr 4.
7
Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.α-半乳糖苷酶A在正常人类肾脏中的分布以及重组α-半乳糖苷酶A在法布里病小鼠肾脏中的蓄积和分布。
J Am Soc Nephrol. 2007 Mar;18(3):698-706. doi: 10.1681/ASN.2006080822. Epub 2007 Feb 7.
8
Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.阿加糖酶β治疗晚期法布里病：一项随机试验。
Ann Intern Med. 2007 Jan 16;146(2):77-86. doi: 10.7326/0003-4819-146-2-200701160-00148. Epub 2006 Dec 18.
9
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.法布里病：多器官系统受累的评估与管理指南
Genet Med. 2006 Sep;8(9):539-48. doi: 10.1097/01.gim.0000237866.70357.c6.
10
Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.用阿加糖酶α对法布里病患儿进行酶替代治疗。
Pediatrics. 2006 Sep;118(3):924-32. doi: 10.1542/peds.2005-2895.
Zotero 插件